These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25986171)

  • 1. A lazy learning-based QSAR classification study for screening potential histone deacetylase 8 (HDAC8) inhibitors.
    Cao GP; Arooj M; Thangapandian S; Park C; Arulalapperumal V; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW
    SAR QSAR Environ Res; 2015; 26(5):397-420. PubMed ID: 25986171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors.
    Cao GP; Thangapandian S; Son M; Kumar R; Choi YJ; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW
    Arch Pharm Res; 2016 Oct; 39(10):1356-1369. PubMed ID: 27542119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.
    Tang H; Wang XS; Huang XP; Roth BL; Butler KV; Kozikowski AP; Jung M; Tropsha A
    J Chem Inf Model; 2009 Feb; 49(2):461-76. PubMed ID: 19182860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.
    Thangapandian S; John S; Lee Y; Kim S; Lee KW
    Int J Mol Sci; 2011; 12(12):9440-62. PubMed ID: 22272142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.
    Thangapandian S; John S; Sakkiah S; Lee KW
    Eur J Med Chem; 2010 Oct; 45(10):4409-17. PubMed ID: 20656379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unveiling critical structural features for effective HDAC8 inhibition: a comprehensive study using quantitative read-across structure-activity relationship (q-RASAR) and pharmacophore modeling.
    Khatun S; Dasgupta I; Islam R; Amin SA; Jha T; Dhaked DK; Gayen S
    Mol Divers; 2024 Aug; 28(4):2197-2215. PubMed ID: 38871969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
    Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
    Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative structure-activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries.
    Pham-The H; Casañola-Martin G; Diéguez-Santana K; Nguyen-Hai N; Ngoc NT; Vu-Duc L; Le-Thi-Thu H
    SAR QSAR Environ Res; 2017 Mar; 28(3):199-220. PubMed ID: 28332438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
    Kashyap K; Kakkar R
    J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding Free Energy (BFE) Calculations and Quantitative Structure-Activity Relationship (QSAR) Analysis of
    Simoben CV; Ghazy E; Zeyen P; Darwish S; Schmidt M; Romier C; Robaa D; Sippl W
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33925246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
    Zhou H; Wang C; Deng T; Tao R; Li W
    J Biomol Struct Dyn; 2018 Jun; 36(8):1966-1978. PubMed ID: 28632421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of inhibitors of Schistosoma mansoni HDAC8 by combining homology modeling, virtual screening, and in vitro validation.
    Kannan S; Melesina J; Hauser AT; Chakrabarti A; Heimburg T; Schmidtkunz K; Walter A; Marek M; Pierce RJ; Romier C; Jung M; Sippl W
    J Chem Inf Model; 2014 Oct; 54(10):3005-19. PubMed ID: 25243797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
    Martínez-Pacheco H; Ramírez-Galicia G; Vergara-Arias M; Gertsch J; Fragoso-Vazquez JM; Mendez-Luna D; Abujamra AL; Cristina CL; Cecilia RM; Mendoza-Lujambio I; Correa-Basurto J
    Anticancer Agents Med Chem; 2017; 17(7):927-940. PubMed ID: 27774878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors.
    Lanka G; Begum D; Banerjee S; Adhikari N; P Y; Ghosh B
    Comput Biol Med; 2023 Nov; 166():107481. PubMed ID: 37741229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies.
    Sixto-López Y; Gómez-Vidal JA; Correa-Basurto J
    Appl Biochem Biotechnol; 2014 Aug; 173(7):1907-26. PubMed ID: 24888409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel two-step QSAR modeling work flow to predict selectivity and activity of HDAC inhibitors.
    Zhao L; Xiang Y; Song J; Zhang Z
    Bioorg Med Chem Lett; 2013 Feb; 23(4):929-33. PubMed ID: 23321563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
    Amin SA; Adhikari N; Jha T
    Future Med Chem; 2018 Jul; 10(13):1589-1602. PubMed ID: 29953251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel potential scaffold for class I HDACs inhibition: An in-silico protocol based on virtual screening, molecular dynamics, mathematical analysis and machine learning.
    Fan C; Huang Y
    Biochem Biophys Res Commun; 2017 Sep; 491(3):800-806. PubMed ID: 28705738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore and QSAR studies to design novel histone deacetylase 2 inhibitors.
    Xiang Y; Hou Z; Zhang Z
    Chem Biol Drug Des; 2012 May; 79(5):760-70. PubMed ID: 22268420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR classification-based virtual screening followed by molecular docking studies for identification of potential inhibitors of 5-lipoxygenase.
    Shameera Ahamed TK; Rajan VK; Sabira K; Muraleedharan K
    Comput Biol Chem; 2018 Dec; 77():154-166. PubMed ID: 30321850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.